Role of stromal CD10 expression in classifying phyllodes tumors
DOI:
https://doi.org/10.18203/2320-6012.ijrms20193935Keywords:
CD10, Immunohistochemistry, Benign, Borderline, Malignant phyllodes tumorAbstract
Background: Phyllodes tumor is a rare fibroepithelial tumor of the breast comprising less than 1% of all primary breast tumor. Phyllodes tumors are classified into benign, borderline and malignant based on histological criteria. Grading of phyllodes tumor is important as it determines the biological behaviour of the tumor. The aim of the present study was to identify the incidence, pathological features of benign, borderline and malignant phyllodes tumors and to compare the CD10 expression in benign, borderline and malignant phyllodes, in order to highlight its diagnostic significance.
Methods: This is a retrospective study conducted in Department of Pathology, Madras Medical College, Chennai for a period of 3 years. The clinical and pathological findings of phyllodes tumors were retrieved from the surgical pathology records. Totally 50 case were selected randomly (38 benign, 6 borderline and 6 malignant) and their representative formalin fixed paraffin embedded tissue samples were subjected to immunohistochemistry for CD10 expression.
Results: In the 38 cases of benign phyllodes tumors, only three cases (7.9%) were CD10 positive. Three out of six cases (50%) of borderline phyllodes tumors showed CD10 positivity, whereas five out of six cases (83.3%) of malignant phyllodes tumor showed CD10 positivity.
Conclusions: CD10 expression correlated well with grade of phyllodes tumors, which is of statistical significance and therefore it can be used in the determination of tumor grade and this may pave way for development of targeted therapies.
References
Palmer ML, De Risi DC, Pelikan A, Patel J, Nemoto J, Rosner D, et al. Treatment options and recurrence potential for cystosarcoma phyllodes. Surg Gynecol Obstet. 1990;170(3):193-6.
Parker SJ, Harries SA. Phyllodes tumours. Postgrad Med J. 2001;77(909):428-35.
Barth RJ. Histologic features predict local recurrence after breast conserving therapy of phyllodes tumors. Breast Cancer Res Treat. 1999; 57(3):291-5.
Moffat CJ, Pinder SE, Dixon AR, Elston CW, Blamey RW, Ellis IO. Phyllodes tumours of the breast: a clinicopathological review of thirty‐two cases. Histopathol. 1995 Sep;27(3):205-18.
Tse GM, Tsang AK, Putti TC, Scolyer RA, Lui PC, Law BK, et al. Stromal CD10 expression in mammary fibroadenomas and phyllodes tumors. J Clin Pathol. 2005;58(2):185-9.
Masri MA,Darwazeh G, Sawalhi S, Mughrabi A, Sughayer M, Al-Shatti M, et al. Phyllodes tumor of the breast: Role of CD10 in predicting metastasis. Ann surg Oncol. 2012 Apr 1;19(4):1181-4.
Bernstein L, Deapen D, Koss RK. The descriptive epidemiology of malignant cystosarcoma phyllodes tumors of the breast. Cancer. 1993;71(10):3020-4.
Margaret IL, Bhuvaneswari R, Cynthia CP, Michael TM, Gayle G, Gerard JN, et al. Giant breast tumors: Surgical management of phyllodes tumors, potential for reconstructive surgery and a review of literature. World J Surg Oncol. 2008;6(1):117.
Nikita AM, Malcolm H, Beverley AC, Shahriar D, Gilks CB, David GH. Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade. Mod Pathol. 2007;20(1):84-9.
Ibrahim WS. comparison of strmal Cd10 expression in benign, borderline and malignant phyllodes tumors among Egyptian female patients. Indian J Pathol Microbiol. 2011;54(4):741-4.
